Court Preliminarily Approves $200 Million Price-Fixing Settlement

September 23, 2025

On September 23, 2025, the Honorable Cynthia M. Rufe preliminarily approved end-payer plaintiffs’ $200 million settlement with Sun Pharmaceuticals and its subsidiary Taro Pharmaceuticals USA.

The settlement resolves claims by FKB’s clients that Taro conspired with other generic pharmaceutical manufacturers to fix prices for certain generic drugs. These claims are part of the largest antitrust multidistrict litigation now pending in the country, in which plaintiffs allege that leading generic pharmaceutical manufacturers fixed prices for more than 180 drugs.

The case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:16-MD-02724, in the U.S. District Court for the Eastern District of Pennsylvania.